UY36564A - Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos - Google Patents

Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos

Info

Publication number
UY36564A
UY36564A UY0001036564A UY36564A UY36564A UY 36564 A UY36564 A UY 36564A UY 0001036564 A UY0001036564 A UY 0001036564A UY 36564 A UY36564 A UY 36564A UY 36564 A UY36564 A UY 36564A
Authority
UY
Uruguay
Prior art keywords
nucleosids
derivatives
antineoplastic agents
replaced
useful
Prior art date
Application number
UY0001036564A
Other languages
English (en)
Inventor
Wythes Martin James
Tran-Dube Michelle Bich
Mctigue Michele Ann
Kumpf Robert Arnold
Mcalpine Indrawan James
Rui Eugene Yuanjin
Tatlock John Howard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY36564A publication Critical patent/UY36564A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Los compuestos de la Fórmula general I, procesos para la preparación de estos compuestos, composiciones que contienen estos compuestos y los usos de estos compuestos.
UY0001036564A 2015-02-24 2016-02-22 Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos UY36564A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562119932P 2015-02-24 2015-02-24
US201562213801P 2015-09-03 2015-09-03
US201662279209P 2016-01-15 2016-01-15

Publications (1)

Publication Number Publication Date
UY36564A true UY36564A (es) 2016-09-30

Family

ID=55451515

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036564A UY36564A (es) 2015-02-24 2016-02-22 Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos

Country Status (29)

Country Link
US (1) US10428104B2 (es)
EP (1) EP3262057B1 (es)
JP (1) JP6584521B2 (es)
KR (1) KR20170119705A (es)
CN (1) CN107278205A (es)
AU (2) AU2016225133B2 (es)
BR (1) BR112017017396A2 (es)
CA (1) CA2921314A1 (es)
CL (1) CL2017002155A1 (es)
CO (1) CO2017008403A2 (es)
CR (1) CR20170384A (es)
CU (1) CU20170105A7 (es)
DO (1) DOP2017000195A (es)
EA (1) EA031895B1 (es)
ES (1) ES2792899T3 (es)
GT (1) GT201700189A (es)
IL (1) IL253637A0 (es)
MX (1) MX2017010844A (es)
NI (1) NI201700095A (es)
PE (1) PE20171449A1 (es)
PH (1) PH12017501413A1 (es)
SG (1) SG11201706050WA (es)
SV (1) SV2017005514A (es)
TN (1) TN2017000357A1 (es)
TW (1) TWI622595B (es)
UA (1) UA118315C2 (es)
UY (1) UY36564A (es)
WO (1) WO2016135582A1 (es)
ZA (1) ZA201705092B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
WO2017153186A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
UA123637C2 (uk) * 2016-03-10 2021-05-05 Янссен Фармацевтика Нв Заміщені аналоги нуклеозидів для застосування як інгібіторів prmt5
MX2019002959A (es) 2016-09-14 2019-07-04 Janssen Pharmaceutica Nv Inhibidores biciclicos condensados de la interaccion de menina-mll.
ES2872003T3 (es) 2016-09-14 2021-11-02 Janssen Pharmaceutica Nv Inhibidores espirobicíclicos de la interacción de menina-MLL
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN115626935A (zh) * 2016-10-03 2023-01-20 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
WO2018152501A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US11220524B2 (en) * 2017-02-20 2022-01-11 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
PL3665179T3 (pl) * 2017-08-09 2021-11-29 Prelude Therapeutics, Incorporated Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5)
JP7328218B2 (ja) * 2017-10-26 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
WO2019110734A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
PE20211444A1 (es) 2017-12-13 2021-08-05 Lupin Ltd Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN111971288B (zh) * 2018-03-14 2023-12-01 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
BR112021015796A2 (pt) * 2019-02-13 2021-10-13 Prelude Therapeutics, Incorporated Inibidor seletivo de proteína arginina metiltransferase 5 (prmt5)
WO2020198323A1 (en) * 2019-03-25 2020-10-01 California Institute Of Technology Prmt5 inhibitors and uses thereof
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
CN114026094B (zh) 2019-06-10 2024-06-25 印度鲁宾有限公司 Prmt5抑制剂
PE20220433A1 (es) 2019-06-12 2022-03-29 Janssen Pharmaceutica Nv Intermedios espirobiciclicos novedosos
CN114599361B (zh) 2019-10-22 2024-07-09 印度鲁宾有限公司 Prmt5抑制剂的药物组合物
MX2022006735A (es) 2019-12-03 2022-07-21 Lupin Ltd Análogos de nucleósidos sustituidos como inhibidores de la prmt5.
PE20231743A1 (es) 2020-08-18 2023-10-31 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak
TW202212341A (zh) 2020-08-18 2022-04-01 美商英塞特公司 製備ｊａｋ１抑制劑之方法及中間體
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
WO2023288197A1 (en) 2021-07-12 2023-01-19 Incyte Corporation Process and intermediates for preparing baricitinib
EP4384519A1 (en) * 2021-08-13 2024-06-19 Albert-Ludwigs-Universität Freiburg Specific small molecule inhibitors that block kmt9 methyltransferase activity and function
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
DE60315164T2 (de) * 2002-08-15 2008-04-30 CV Therapeutics, Inc., Palo Alto Partielle und volle agonisten von a1-adenosinrezeptoren
EA201190178A1 (ru) * 2009-03-20 2012-06-29 Алиос Биофарма, Инк. Замещённые нуклеозидные и нуклеотидные аналоги
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
US9416154B2 (en) * 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013044030A1 (en) * 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
CN108026136A (zh) * 2015-08-06 2018-05-11 奇默里克斯公司 作为有用的抗病毒剂的吡咯并嘧啶核苷及其类似物

Also Published As

Publication number Publication date
EP3262057B1 (en) 2020-04-15
GT201700189A (es) 2019-06-10
SG11201706050WA (en) 2017-09-28
TN2017000357A1 (en) 2019-01-16
IL253637A0 (en) 2017-09-28
EA201791563A1 (ru) 2018-01-31
US20160244475A1 (en) 2016-08-25
AU2016225133A1 (en) 2017-08-10
CN107278205A (zh) 2017-10-20
PH12017501413A1 (en) 2018-01-29
WO2016135582A1 (en) 2016-09-01
TW201643176A (zh) 2016-12-16
CR20170384A (es) 2017-11-16
KR20170119705A (ko) 2017-10-27
NI201700095A (es) 2017-10-31
AU2016225133B2 (en) 2018-11-29
CO2017008403A2 (es) 2017-10-31
BR112017017396A2 (pt) 2018-04-03
TWI622595B (zh) 2018-05-01
AU2018278842A1 (en) 2019-01-03
JP2018510850A (ja) 2018-04-19
DOP2017000195A (es) 2017-10-15
SV2017005514A (es) 2018-04-11
JP6584521B2 (ja) 2019-10-02
PE20171449A1 (es) 2017-10-02
ES2792899T3 (es) 2020-11-12
ZA201705092B (en) 2019-06-26
US10428104B2 (en) 2019-10-01
EP3262057A1 (en) 2018-01-03
UA118315C2 (uk) 2018-12-26
CL2017002155A1 (es) 2018-05-11
EA031895B1 (ru) 2019-03-29
CU20170105A7 (es) 2017-10-05
CA2921314A1 (en) 2016-08-24
MX2017010844A (es) 2017-12-07

Similar Documents

Publication Publication Date Title
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
NI201800128A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
ECSP16074478A (es) Compuestos novedosos
CL2018001837A1 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
ECSP17069696A (es) Compuestos novedosos
CO2018004581A2 (es) Compuestos de criptoficina y productos conjugados, y sus métodos de preparación
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2017000151A1 (es) Derivados de piridona
CR20180181A (es) Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221104